Start Year: 2014 | Frequency: Half-Yearly
ISSN: 2520-3096
DOI: 10.21522/TIJCR.2014
About Clinical Research
Texila International Journal of Clinical Research (TIJCR) is an open-access, peer-reviewed journal that publishes innovative studies and applied research in clinical research, drug discovery, clinical trials, and regulatory affairs. It serves as a global platform for researchers and practitioners to share insights that advance healthcare practices, strengthen compliance standards, and support evidence-based medicine.
Journal Metrics
Journal Views
9221
Published Articles: 118
Acceptance Rate: 30%
Journal Metrics: Texila International Journal of Clinical Research
| Metric | Details |
|---|---|
| Journal Views (as of 2025) | 9221 |
| Total Articles Published | 118 |
| Articles Published in Previous Issue | 2 |
| Submission to First Decision | 12 days (initial editorial screening from the date of submission) |
| Average time from submission to acceptance | Peer review and editorial decision typically take 120 days; publication follows the next scheduled issue (February/August) |
| Average Review Rounds | 2 |
| Acceptance Rate | 40% |
| Publication Schedule | Half-Yearly (Issue Months: February, August) |
Aims & Scope
TIJCR focuses on clinical trials, drug discovery, quality compliance, and ethical/legal issues in healthcare by publishing original research, reviews, case reports and case studies. The journal emphasizes methodological rigor, ethical compliance, and innovative approaches to clinical research, supporting evidence-based medicine and healthcare delivery.
It also encourages interdisciplinary studies that connect clinical science with policy, quality assurance, and disaster medicine. By fostering collaboration among researchers, practitioners, and regulators, TIJCR aims to improve clinical practices, strengthen compliance frameworks, and contribute to global healthcare innovation.
Topics Covered by TIJCR
TIJCR welcomes manuscripts in the following areas:
- Clinical Trials and Methodologies
- Drug Discovery and Development
- Regulatory Affairs and Compliance
- Ethical and Legal Issues in Healthcare
- Disaster Medicine and Emergency Research
- Data Auditing and Quality Assurance in Clinical Studies
Call for Papers
Texila International Journal of Clinical Research
Authors cordially invited to submit papers for the upcoming edition Volume 7 Issue 1, August 2026.
Submission Deadline:
5th JUL 2026
Issue Publication:
28th AUG 2026
Pricing
Texila International Journal of Clinical Research
- Texila American University (TAU) Researchers: 100 USD
- Non-TAU Researchers/Institutional Partner: 150 USD
Our Articles are Available
Indexation of a journal is considered a reflection of its quality and increases its visibility, thereby promoting greater usage and impact.
Editorial Board
Dr. N. Vanitha Rani
Editor-in-Chief, Texila International Journal of Clinical Research
Affiliation/Institution: Department of Pharmacy, Sri Ramachandra University, Chennai, Tamil Nadu, India
Country: India
Dr. N. Vanitha Rani, M.Pharm., Ph.D. is an accomplished academician and researcher in the field of Pharmacy Practice with over 15 years of teaching and research experience. She has served as Lecturer and Assistant Professor in the Department of Pharmacy Practice at Sri Ramachandra University and has made significant contributions to clinical pharmacy, pharmacoeconomics, pharmacovigilance, medication safety, and patient counseling.
Dr. Vanitha Rani completed her B.Pharm from Madras Medical College, M.Pharm (Pharmacy Practice), and Ph.D. from Sri Ramachandra University. She has guided numerous undergraduate and postgraduate research projects and has published more than 30 research articles in national and international journals.
Her research focuses on medication adherence, clinical outcomes, pharmacoeconomics, chronic disease management, and pharmaceutical care. She has presented research at national and international conferences and received awards for outstanding research contributions. Dr. Vanitha Rani is also an active member of several professional organizations, including the Association of Pharmacy Teachers of India and the Indian Pharmaceutical Association.
She remains committed to advancing pharmacy education, clinical research, and patient-centered healthcare through teaching, mentorship, and scholarly activities.
Mohammad Junaid Memon
Peer Reviewer, Texila International Journal of Clinical Research
Affiliation/Institution: Senior Director, Global Pharmacovigilance Operations & Strategy, San Jose, California
Country: USA
Researcher Links: [LinkedIn]
Mohammad Junaid Memon – Director, Global Pharmacovigilance Operations & Strategy — Ascendis Pharma
Mr. Memon is Director, Global Pharmacovigilance Operations & Strategy at Ascendis Pharma, where he holds enterprise accountability for safety strategy, benefit-risk oversight, signal detection, aggregate reporting, and regulatory compliance across an oncology and endocrinology portfolio spanning 35+ countries.
With over 16 years of progressive global pharmacovigilance experience, he has led safety functions across both clinical-stage and commercial pharmaceutical settings. Earlier in his career he built the pharmacovigilance function from inception at Athenex through US NDA and EMA MAA submissions, directly leading an internal global team across the United States, Argentina, and Taiwan. He carries a clean regulatory inspection record across the FDA, EMA, DKMA, and MHRA.
His areas of expertise include ICSR lifecycle management, signal detection and risk management (RMP/REMS), aggregate safety reporting (PBRER, PADER, DSUR, PSUR), Argus Safety database design and upgrade, submission rule automation, and the application of AI-enabled tooling to strengthen submission integrity, signal management, and quality oversight. He has designed and built internal pharmacovigilance decision and quality-control tools encoding global submission rules across 35+ countries, used to independently validate Argus-generated reports and trend vendor case-review quality.
Mr. Memon holds a Bachelor of Homoeopathic Medicine & Surgery (BHMS) from Smt. C.M.P. Homoeopathic Medical College, Mumbai, an MBA in Strategic Management from Pace University, New York, an MBA in Healthcare Management from Goldey-Beacom College, Delaware, and a Postgraduate Diploma in Clinical Research from the Institute of Clinical Research India, Mumbai.
He has been associated with Texila International Journal of Clinical Research as an Editorial Board Member and Peer Reviewer since 2018, and also serves on the editorial board of Acta Scientific Medical Sciences. He advises early-stage pharmacovigilance technology developers building AI-enabled ICSR intake and case-processing platforms.
Dr. Dharani Gokul Munirathinam
Peer Reviewer, Texila International Journal of Clinical Research
Affiliation/Institution: Medical Scientist/Founder of Clinformatik LLC. USA
Country: USA
Dr. Dharani Gokul Munirathinam
Dr. Dharani Gokul Munirathinam is a medical doctor (MBBS) and Pharmacovigilance professional with over 13 years of experience in global drug and medical device safety, risk management, clinical research, and healthcare operations. He possesses extensive expertise in both clinical trial and post-marketing pharmacovigilance, including signal detection, aggregate reporting, safety surveillance, regulatory compliance, and risk minimization strategies.
Throughout his career, Dr. Dharani has held leadership positions with globally recognized organizations, including Amgen, Baxter, Bristol Myers Squibb, and Accenture. He has successfully led end-to-end pharmacovigilance operations, developed safety processes and standard operating procedures, managed multidisciplinary teams, and supported regulatory submissions across international markets.
His professional strengths include pharmacovigilance consulting, medical review, safety data evaluation, quality and compliance management, audit readiness, process improvement, and stakeholder engagement. He has also contributed to the development of risk management plans, aggregate safety reports, and signal management strategies for pharmaceutical and medical device products.
Dr. Dharani is recognized for his commitment to patient safety, operational excellence, and innovation. He received the R&D Star Award from Bristol Myers Squibb for his contribution to improving pharmacovigilance reporting processes. In addition to his industry experience, he has been actively involved in medical education, research publications, professional associations, and editorial activities within the healthcare and clinical research community.
His continued focus on advancing drug safety and risk management reflects his dedication to improving healthcare outcomes and supporting the development of safe and effective therapeutic products.
Dr.Dharani Gokul Munirathinam membership details are
- Member Indian Medical Association, Chennai Branch, India
- Pharmacovigilance Expert Committee Member Indian Drug Manufactures Association (IDMA)
- Associate Member American College of Clinical Pharmacy (ACCP)
- Editorial Board Member South American Journal of Clinical Research in the Texila American University.
- Consultant Editor Scottish University Medical Journa